Hot Investor Mandate 3: China-based Firm Invests in Preclinical Drugs in Oncology and Chronic Diseases

16 Mar

The biotech and healthcare subsidiary company of a large real estate corporation in China is interested in biotech technology, products and services with large potential in the Chinese market. The firm aims to launch them in China through partnership, investment and cooperation. Typical equity investments range from US$0.7-1.5 million (RMB 5-10 million), up to 3.5 million in later stage companies. The firm prefers to co-invest in a round with a strong, reputable lead. The firm considers opportunities from around the world with a focus on China, the US, and Australia.

The firm is interested in preclinical therapeutic projects in oncology, chronic diseases such as diabetes, and other disease indications with large market potential. The firm is open to all therapeutic modalities.

The firm is looking for experienced teams backed by strong lead investors. The firm may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: